FIGO Statement: Vaccination in pregnancy

dc.contributor.authorNassar, Anwar H.
dc.contributor.authorVisser, Gerard H.A.
dc.contributor.authorNicholson, Wanda Kay
dc.contributor.authorRamašauskaite, Diana
dc.contributor.authorKim, Yoonha
dc.contributor.authorBarnea, Eytan Robert
dc.contributor.authorVisser, Gerard H.A.
dc.contributor.authorBarnea, Eytan Robert
dc.contributor.authorEscobar, Maria Fernanda
dc.contributor.authorPacagnella, Rodolfo De Carvalho
dc.contributor.authorRamašauskaite, Diana
dc.contributor.authorTheron, Gerhard Barnard
dc.contributor.authorWright, Alison
dc.contributor.departmentObstetrics and Gynecology
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:08:09Z
dc.date.available2025-01-24T12:08:09Z
dc.date.issued2021
dc.description.abstractPregnant women and their fetuses are among the vulnerable populations that can be severely affected by communicable diseases. As such, some vaccines such as the influenza and the Tdap (tetanus toxoid, reduced diphtheria toxoid, and acellular pertussis) vaccines are strongly recommended in each pregnancy, with generally safe profiles. Other vaccines can be offered based on risk factors, and only when the benefits of receiving them outweigh the risks. Development of vaccines against group B streptococcus infection and respiratory syncytial virus infection are of great importance. In this paper, the recommendations for administration of each vaccine during pregnancy are discussed. The FIGO Committee for Safe Motherhood and Newborn Health Committee endorses the recommendations to vaccinate all pregnant women against influenza during the influenza season at any time during the pregnancy and against Tdap preferably between the 27th and 36th weeks of pregnancy in each pregnancy. © 2020 International Federation of Gynecology and Obstetrics
dc.identifier.doihttps://doi.org/10.1002/ijgo.13456
dc.identifier.eid2-s2.0-85097012075
dc.identifier.pmid33128249
dc.identifier.urihttp://hdl.handle.net/10938/31734
dc.language.isoen
dc.publisherJohn Wiley and Sons Ltd
dc.relation.ispartofInternational Journal of Gynecology and Obstetrics
dc.sourceScopus
dc.subjectBest practice
dc.subjectMaternity care
dc.subjectSafe motherhood
dc.subjectVaccination
dc.subjectAdult
dc.subjectDiphtheria-tetanus-acellular pertussis vaccines
dc.subjectFemale
dc.subjectHumans
dc.subjectInfant, newborn
dc.subjectInfluenza vaccines
dc.subjectPregnancy
dc.subjectRisk factors
dc.subjectVaccines
dc.subjectVulnerable populations
dc.subjectDiphtheria pertussis tetanus vaccine
dc.subjectHepatitis a vaccine
dc.subjectHepatitis b vaccine
dc.subjectInfluenza vaccine
dc.subjectMeningococcus vaccine
dc.subjectPneumococcus vaccine
dc.subjectVaccine
dc.subjectArticle
dc.subjectDiphtheria
dc.subjectDrug contraindication
dc.subjectHepatitis a
dc.subjectHepatitis b
dc.subjectHuman
dc.subjectInfluenza
dc.subjectInfluenza vaccination
dc.subjectMaternal care
dc.subjectMeningococcosis
dc.subjectMother
dc.subjectPertussis
dc.subjectPneumococcal infection
dc.subjectPregnant woman
dc.subjectPriority journal
dc.subjectRisk factor
dc.subjectTetanus
dc.subjectNewborn
dc.subjectProcedures
dc.subjectVulnerable population
dc.titleFIGO Statement: Vaccination in pregnancy
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2021-6261.pdf
Size:
478.93 KB
Format:
Adobe Portable Document Format